BECAIT
BECAIT
Bezafibrate Coronary Atherosclerosis Intervention Trial. A trial assessing the ability of a lipid-altering agent, bezafibrate, to retard the development of coronary lesions.Conclusion
Long-term use of bezafibrate slows the progression of coronary atheromas and coronary events in young male survivors of acute myocardial infarction.